|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.38 USD | +0.03% |
|
-.--% | +0.22% |
| 09/01 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2000 Value Benchmark | CI |
| 09/01 | Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 2500 Value Benchmark | CI |
| Market Cap | 695.9Cr 612.04Cr 568.58Cr 522.94Cr 980.69Cr 67TCr 998.27Cr 6.8TCr 2.65TCr 33TCr 2.61TCr 2.56TCr 1,14000Cr | P/E 2023 |
-3.03x | P/E 2024 | -1.01x |
|---|---|---|---|---|---|
| Enterprise Value | 677.27Cr 595.66Cr 553.37Cr 508.94Cr 954.44Cr 66TCr 971.55Cr 6.62TCr 2.58TCr 32TCr 2.54TCr 2.49TCr 1,11000Cr | EV / Sales 2023 |
0.64x | EV / Sales 2024 | 84.5x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: Cidara Therapeutics
| 1 day | +0.03% | ||
| Current year | +0.22% |
| Current year | 220.47 |  | 221.42 |
| 1 year | 56.53 | | 221.42 |
| 3 years | 10 | | 221.42 |
| 5 years | 8 | | 221.42 |
| 10 years | 8 | | 259 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Karbe
DFI | Director of Finance/CFO | 58 | 24/02/2025 |
Corrina Pavetto
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Chief Tech/Sci/R&D Officer | - | 01/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 07/01/26 | Issuer sale | Director | 41,100 | 0.1621% | ||
| 07/01/26 | Issuer sale | Director | 42,920 | 0.1693% | ||
| 07/01/26 | Issuer sale | Director | 35,390 | 0.1396% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 6.39Cr 5.62Cr 5.22Cr 4.8Cr 9.01Cr 618.87Cr 9.17Cr 62Cr 24Cr 301.86Cr 24Cr 23Cr 1.05TCr | 12.75L 11.21L 10.42L 10L 17.97L 12Cr 18.29L 1.25Cr 48.59L 6.02Cr 47.87L 46.83L 21Cr |
| Net income | -2.29Cr -2.02Cr -1.87Cr -1.72Cr -3.23Cr -222.07Cr -3.29Cr -22Cr -8.74Cr -108.32Cr -8.61Cr -8.42Cr -375.78Cr | -17Cr -15Cr -14Cr -13Cr -24Cr -1.64TCr -24Cr -165.93Cr -65Cr -802.18Cr -64Cr -62Cr -2.78TCr |
| Net Debt | -3.09Cr -2.72Cr -2.52Cr -2.32Cr -4.35Cr -299.25Cr -4.43Cr -30Cr -12Cr -145.96Cr -12Cr -11Cr -506.38Cr | -19Cr -16Cr -15Cr -14Cr -26Cr -1.8TCr -27Cr -181.97Cr -71Cr -879.75Cr -70Cr -68Cr -3.05TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CDTX Stock
Select your edition
All financial news and data tailored to specific country editions
